We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00271687
Recruitment Status : Completed
First Posted : January 4, 2006
Last Update Posted : February 25, 2016
Information provided by (Responsible Party):

Study Description
Brief Summary:
This study aims to provide preliminary data on the feasibility and outcomes of a 12 week exercise program on the quality of life of men with hormone refractory prostate cancer receiving docetaxel-based chemotherapy.

Condition or disease Intervention/treatment Phase
Prostatic Neoplasms Neoplasm Metastasis Palliative Care Behavioral: Exercise training Phase 2

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer
Study Start Date : February 2006
Primary Completion Date : November 2007
Study Completion Date : November 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Docetaxel
U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :
  1. feasibility (recruitment, adherence, safety)

Secondary Outcome Measures :
  1. quality of life
  2. functional abilities

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • diagnosis of prostate cancer
  • receiving docetaxel-based chemotherapy at the CCI
  • age 18 years or over
  • approval of oncologist
  • informed written consent

Exclusion Criteria:

  • life expectancy less than 6 months
  • Karnofsky performance score less than 70
  • contraindications for exercise (e.g. uncontrolled cardiac, respiratory, hypertensive or psychiatric disorder)
  • unable to understand, read, write and speak English
  • unable or unwilling to attend supervised exercise sessions 3 times weekly
  • unable or unwilling to complete outcome assessments
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00271687

Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Cross Cancer Institute
Principal Investigator: Kerry Courneya, M.D. Cross Cancer Institute
More Information

Responsible Party: AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT00271687     History of Changes
Other Study ID Numbers: SP-14-0049 / 22262
First Posted: January 4, 2006    Key Record Dates
Last Update Posted: February 25, 2016
Last Verified: March 2012

Keywords provided by AHS Cancer Control Alberta:
exercise therapy
activities of daily living
quality of life

Additional relevant MeSH terms:
Prostatic Neoplasms
Neoplasm Metastasis
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Neoplastic Processes
Pathologic Processes
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs